Anthracycline News and Research

RSS

Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.

3 Jan 2022

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.

11 Nov 2021

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

New genetic classifier can predict the sensitivity of neoadjuvant chemotherapy for breast cancer

A research team by Prof. YANG Wulin and DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences recently proposed a genetic classifier that can predict the sensitivity of neoadjuvant chemotherapy for breast cancer in the field of tumor molecular markers.

15 Sep 2021

Leducq Foundation awards $7 million for vascular malformation research

Luisa Iruela-Arispe, PhD, the Stephen Walter Ranson Professor of Cell Biology and chair of Cell and Developmental Biology, is the North American coordinator for an international collaboration that has received a five-year, $7 million Transatlantic Networks of Excellence Program award from the Leducq Foundation.

20 Aug 2021

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors

Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects.

30 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Study finds high prevalence of cardiovascular conditions in male breast cancer patients

Male breast cancer patients were found to have a high prevalence of cardiovascular conditions, in a small study of this rare patient population presented at the American College of Cardiology's Advancing the Cardiovascular Care of the Oncology Patient Virtual course.

25 Jan 2021

Statins may protect the heart from damaging side-effects of early breast cancer treatment

New research from UHN's Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment.

6 Jan 2021

Cancer chemotherapy changes the function of cells that repair heart injury

Cancer chemotherapy changes the function of cells that repair heart injury, researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) discovered.

30 Sep 2020

Gene could predict treatment response in certain breast cancer patients

Scientists have identified a gene which if present in certain breast cancer patients indicates how they will respond to specific therapies.

6 Aug 2020

Simple blood test offers early warning of chemotherapy-related cardiac dysfunction

Scientists have identified a collection of biomarkers that together signal that a person's cancer treatment may be harming their heart.

27 Apr 2020

Researchers identify protein that plays critical role in cancer treatment-related heart damage

Many cancers can be successfully treated, but treatment itself often comes with risks as well. Cancer therapy that uses anthracyclines--a class of commonly used chemotherapy drugs--has been associated with heart damage that can eventually result in heart failure. It is thought to be the reason why heart disease is a leading cause of death in cancer survivors, immediately following cancer recurrence.

9 Apr 2020

Statins may protect against heart damage caused by breast cancer therapies

Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but can they also help guard against heart damage caused by certain breast cancer therapies?

19 Mar 2020

Obesity linked to increased risk of cardiotoxicity in chemotherapy-treated patients with breast cancer

Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease.

23 Dec 2019

Leukemia patients treated with common cancer drug have heightened risk of heart failure

Patients with acute lymphoblastic leukemia or acute myeloid leukemia who are treated with anthracyclines are at a heightened risk of heart failure- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine.

17 Dec 2019

Yale study highlights the need to develop effective, less toxic approaches to treat AML patients

A new study by Yale Cancer Center researchers shows understanding treatment patterns for patients with acute myeloid leukemia is vital to develop strategies to improve outcomes.

9 Dec 2019

Cancer patients receiving common heart drugs have less heart damage from cancer therapy

Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology.

4 Dec 2019

Cardiac resynchronization therapy improves heart function in cancer survivors

A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association reports.

12 Nov 2019

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”

27 Aug 2019